Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial. The addition of this drug ...

Golimumab—a human monoclonal anti-TNF antibody—is effective for the treatment of patients with moderate-to-severe ulcerative colitis, according to new findings published in the journal ...

Golimumab (Simponi), taken with a drug called methotrexate, is recommended as a possible treatment for some adults with severe active rheumatoid arthritis in the same circumstances as other drugs for ...

Golimumab is a human monoclonal antibody specific for tumor necrosis factor α that has already been approved for the treatment of several autoimmune conditions in adults and children. Whether ...

Golimumab (also known as Simponi) stops TNF-alpha working in the body, which helps to reduce swelling and joint damage in people with rheumatoid arthritis. When golimumab is used to treat rheumatoid ...

Golimumab subcutaneous injectable solution is available as a brand-name drug. It’s not available as a generic drug. Brand name: Simponi. Golimumab comes in two injectable forms: a subcutaneous ...

November 24, 2009 (San Diego, California) — A new fully human monoclonal antibody (MAb) against TNF, golimumab (CNTO148, Centocor/Schering-Plough), is close to entering the market. Results from ...

Several controlled clinical trials have proven the efficacy of golimumab in reducing symptom severity and improving disease outcomes in patients with psoriatic arthritis. SAN FRANCISCO ...